Study title: Krymchantowski-A-V, Filho-P-F-M, Bigal-M-E. Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia : an international journal of headache, {Cephalalgia}, Jul 2006, vol. 26, no. 7, p. 871-4,Krymchantowski-A-V, Filho-P-F-M, Bigal-M-E. Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia : an international journal of headache, {Cephalalgia}, Jul 2006, vol. 26, no. 7, p. 871-4,
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Digestive System Diseases | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: TRIMEBUTINE | |||||
| ATC code: A03AA05 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |